ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife(TM) Algal Biomass
MWN-AI** Summary
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech research company specializing in algal-derived products, has announced a significant commercial-scale manufacturing agreement with Cyanotech Corporation, a leader in microalgae cultivation. This partnership aims to bolster ZIVO’s Zivolife™ product line, which is targeted at the animal health, human nutrition, and functional ingredient markets.
Cyanotech, with over four decades of experience in microalgae production, operates a 96-acre facility at the Natural Energy Laboratory of Hawaii. It is renowned for its cultivation expertise, having successfully produced major products like BioAstin® Astaxanthin and Hawaiian Spirulina Pacifica®. This collaboration marks a pivotal point in ZIVO’s journey toward meeting rising global demand, as Cyanotech's pristine operational environment and established infrastructure will enhance production reliability and scalability.
ZIVO CEO John Payne emphasized that securing this partnership with Cyanotech serves as a transformative step for the company, providing the assurance needed to respond effectively to anticipated market needs. The collaboration signifies ZIVO's strategy to create a robust supply chain, positioning the company to harness initial commercial revenue streams. Cyanotech President Matthew Custer echoed this sentiment, highlighting the scalable production capacity that will enable ZIVO to meet both initial and future demands as it enhances its proprietary algal biomass products.
Overall, this partnership not only solidifies ZIVO's operational capabilities but also reflects confidence in its proprietary technologies and their market appeal, potentially paving the way for greater commercialization of its algal-based offerings. As ZIVO Bioscience continues to advance in this sector, the collaboration with Cyanotech signals a promising trajectory amidst a growing global focus on sustainable and health-oriented product solutions.
MWN-AI** Analysis
ZIVO Bioscience (OTCQB: ZIVO) has recently secured a manufacturing agreement with Cyanotech Corporation, positioning ZIVO favorably to meet expected global demand for its Zivolife™ algal biomass solutions. This partnership is particularly significant given Cyanotech’s four decades of expertise in cultivating microalgae, which adds credibility and operational capability to ZIVO’s ambitions in the nutraceutical and animal health sectors.
As a financial analyst, I see this agreement as a pivotal moment for ZIVO, enhancing its potential to scale production and generate revenue streams. The collaboration not only ensures a reliable supply chain but also leverages Cyanotech’s established production infrastructure and market reputation. Investors should note the strategic importance of such partnerships in the biotechnology space, especially for companies at ZIVO’s growth stage.
This move also signifies ZIVO’s transition from R&D to commercial readiness, aligning with increasing global consumer interest in natural, algae-derived nutritional products. The market for functional ingredients is expanding, and ZIVO's entry with a differentiated product line could cater to emerging health consciousness trends. However, the success of ZIVO hinges on its ability to meet production demands and navigate regulatory frameworks, which presents inherent risks.
Investors should consider the potential upside if ZIVOLife™ achieves market traction, but should remain cautious about the uncertainties outlined in ZIVO's forward-looking statements. The company’s future performance could be influenced by production scalability, market acceptance, and the efficacy of its products in consumer applications.
In conclusion, while the partnership with Cyanotech solidifies ZIVO’s manufacturing capabilities and enhances its competitive position, I recommend closely monitoring market developments and regulatory milestones. A watchful approach may provide investors with insights into pricing power and demand trends in this burgeoning segment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand
Zivo Bioscience, Inc. (OTCQB: ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the signing of a manufacturing agreement with Cyanotech Corporation to grow, cultivate and process ZIVO's proprietary algal biomass for its Zivolife™ product line.
ZIVO is advancing Zivolife™ toward commercial applications across animal health, human nutrition and functional ingredients markets. This agreement with Cyanotech, one of the world's most established microalgae producers, represents a significant milestone in ZIVO's commercial readiness as the Company prepares to meet anticipated demand from existing and prospective partners across global markets.
A World-Class Production Partner
Cyanotech brings unmatched depth of experience and infrastructure to the partnership, including:
- Over 40 years of continuous microalgae cultivation , operating since 1984 on the Kailua-Kona Coast of Hawaii's Big Island
- 96-acre production facility at the Natural Energy Laboratory of Hawaii Authority (NELHA), one of the largest dedicated microalgae farms in the world
- Multi-species expertise with proven commercial-scale cultivation of Spirulina and Haematococcus, and now ZIVO’s proprietary Kelbsormidium Flaccidum, across dietary supplement, nutraceutical and food applications
- Pristine growing environment located in a designated Biosecure Zone with abundant year-round sunlight, clean air, clean lava-filtered water and low rainfall enabling 12-month production cycles
- cGMP operations with rigorous third-party quality control and FDA regulatory compliance
- GRAS (Generally Recognized as Safe) certification for microalgae products intended for food use
- Proven scale with production volumes that have driven consistent year-over-year growth including recent financial results reflecting nearly 20% revenue growth
"Securing Cyanotech as our manufacturing partner is a transformational step for ZIVO," said John Payne, CEO and Chairman of ZIVO Bioscience. "Their decades of operational expertise, scale of production and commitment to quality provide the infrastructure we need to confidently respond to global market demand for Zivolife™. We are building a reliable supply chain for our partners, which is a critical step toward enabling initial commercial revenues."
"Cyanotech is proud to partner with ZIVO Bioscience and bring our cultivation expertise to the production of Zivolife™. The agreement provides ZIVO with scalable production capacity to support initial commercial volumes, with the ability to expand as demand increases," said Matthew Custer, President and CEO of Cyanotech Corporation. "ZIVO has developed a compelling proprietary algal biomass with strong consumer appeal, and we look forward to supporting their success."
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
About Cyanotech Corporation
Cyanotech Corporation is a world leader in microalgae technology with more than 40 years of experience producing high-value natural products derived from microalgae. Operating a 96-acre facility on the Kailua-Kona Coast of Hawaii, Cyanotech produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica® using patented, proprietary cultivation technology. All Cyanotech products are GRAS-certified and GMP-certified for dietary supplement use. Please visit www.cyanotech.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected timeframe for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes there is a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our preclinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials; our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this news release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260406825897/en/
ZIVO Bioscience
John B. Payne, CEO
jpayne@zivobioscience.com
Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com
FAQ**
How does the partnership with Cyanotech Corporation enhance Zivo Bioscience Inc. ZIVO's ability to meet anticipated global demand for its Zivolife™ product line in the health and nutrition markets?
What specific advantages does the 40-year experience of Cyanotech bring to Zivo Bioscience Inc. ZIVO's manufacturing capabilities for its proprietary algal biomass?
What are the expected commercial applications of Zivo Bioscience Inc. ZIVO's Zivolife™ product line, and how may this partnership with Cyanotech influence growth in these sectors?
Can you elaborate on the risk factors associated with Zivo Bioscience Inc. ZIVO's forward-looking statements regarding product commercialization and market acceptance outlined in the recent press release?
**MWN-AI FAQ is based on asking OpenAI questions about Zivo Bioscience Inc. (OTC: ZIVO).
NASDAQ: ZIVO
ZIVO Trading
-18.23% G/L:
$3.05 Last:
2,552 Volume:
$3.73 Open:
